NCT05142319 - Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] | Biotech Hunter

Enrollment

326

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

June 1, 2023

Study Completion Date

May 7, 2024

Conditions

COVID-19

Interventions

BIOLOGICAL

Homologous mRNA booster vaccine

Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.

BIOLOGICAL

Heterologous mRNA booster vaccine

Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.

BIOLOGICAL

COVAXIN

Single intradermal injection at 6ug (0.5ml) per dose.

BIOLOGICAL

Nuvaxovid

Single intradermal injection at 5mcg (0.5mL) per dose.

Trial Locations (1)

National Centre for Infectious Diseases (NCID), Singapore

All Listed Sponsors

collaborator

A*Star

OTHER

collaborator

KK Women's and Children's Hospital

OTHER_GOV

collaborator

Duke-NUS Graduate Medical School

OTHER

lead

Tan Tock Seng Hospital

OTHER